Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06596252 · ClinicalTrials.gov registry record · Phase 3
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
A Phase 3 study of Eosinophilic Esophagitis, sponsored by Dr. Falk Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 308
- Enrollment target
- 20
- Study locations
NCT06596252: Recruiting Phase 3 study of Eosinophilic Esophagitis, sponsored by Dr. Falk Pharma.
NCT06596252 is a Phase 3 study of Eosinophilic Esophagitis that is actively recruiting participants, run by Dr. Falk Pharma. The registered enrollment target is 308 participants, below the 857-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06596252, a Phase 3 study of Eosinophilic Esophagitis, is actively recruiting participants, sponsored by Dr. Falk Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 308 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Primary Outcome
Histological assessment of biopsies taken at end of treatment visit
Conditions Studied
Interventions
- DRUG Budesonide
Study Locations (20)
California
- Dr. Falk Investigational Site - La Jolla
- Dr. Falk Investigational Site - Lomita
- Dr. Falk Investigational Site - San Diego
Florida
- Dr. Falk Investigational Site - Doral
- Dr. Falk Investigational Site - New Port Richey
Louisiana
- Dr. Falk Investigational Site - Houma
- Dr. Falk Investigational Site - Marrero
Michigan
- Wyoming - Ann Arbor
- Dr. Falk Investigational Site - Wyoming
New Jersey
- Dr. Falk Investigational Site - Freehold
- Dr. Falk Investigational Site - Jackson
Ohio
- Dr. Falk Investigational Site - Cleveland
- Dr. Falk Investigational Site - Mentor
Arizona
- Dr. Falk Investigational Site - Scottsdale
Arkansas
- Dr. Falk Investigational Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
What NCT06596252 shows while recruiting
NCT06596252 is an interventional study that assigns participants to a tested intervention. The registered 308 participants enrollment target is mid-sized for trials with a published cap, below the 857-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which Budesonide is the first listed.
NCT06596252 names 20 study sites across 13 states, led by California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06596252 about?
NCT06596252 is a clinical study titled "Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE". The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
What is the current status of trial NCT06596252?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 308 participants. The study started on 2021-05-21. Estimated completion is 2027-03.
What conditions does trial NCT06596252 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT06596252?
The interventions under investigation include: Budesonide (DRUG).
Who is sponsoring clinical trial NCT06596252?
This trial is sponsored by Dr. Falk Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06596252 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06596252's enrollment target sits among peer trials
308 12th of 44 higher than 33 of 44 other Eosinophilic Esophagitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
ACTIVE NOT RECRUITING · Phase 3
-
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
COMPLETED · Phase 3
-
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)
COMPLETED · Phase 3
-
Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)
RECRUITING
-
Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- NCT06233942 · 308 participants · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI